Kougialis S, Skopelitis E, Gialernios T, Nikolaou S, Kroustalis A, Katsadorou E, Gialernios K, Zervou A, Gika E, Polydorou A, Polydorou V, Drakoulis C, Iliopoulos N, Dermitzakis I, Mpilinis H, Polydorou A
2nd Department of Internal Medicine, General Hospital of Nikaia and Piraeus, Pireaus, Greece.
Int Angiol. 2010 Aug;29(4):338-47.
Oxidized low-density lipoprotein (oxLDL) is a pivotal factor of the atheromatous process. Statins reduce atheromatosis and cardiovascular risk. The aim of the present study was to investigate the effect of statin therapy on circulating oxLDL and the possible impact of such effect on stenosis due to carotid artery atheromatosis.
A total of 100 patients (76 males, median age 68 years) with carotid atheromatosis were enrolled. Those with stenosis >70% (n=50) were pre-treated with carotid angioplasty, whereas those with <70% were treated conservatively. Both groups were given low-dose atrorvastatin, tittered to maintain LDL cholesterol <100 mg/dL. Anthropometrics, complete lipid profile, and oxLDL were obtained in 1, 3, 6 and 12 months. Stenosis was evaluated by ultrasonography at baseline and 12 months.
Lipid profile significantly improved at 12 months and oxLDL fell from 62.26+/-22.03 mg/dL at baseline to 44.49+/-21.75 mg/dL at 12 months (P<0.001). In the invasively pretreated group no restenosis was noticed; in the conservatively treated group a significant reduction of stenosis was demonstrated (47.6+/-13.2% vs 37.7+/-15.7%, P<0.001). The decrease of oxLDL correlated with the reduction of stenosis (r=0.17, P=0.018). In multivariate analysis, oxLDL was an independent risk factor for re-stenosis (hazard ratio=4.319, P<0.001).
A marked reduction of oxLDL was shown in patients with carotid atheromatosis treated with low-dose atorvastatin. Moreover, oxLDL could be a measure of the degree of stenosis in such patients.
氧化型低密度脂蛋白(oxLDL)是动脉粥样硬化进程的关键因素。他汀类药物可减轻动脉粥样硬化并降低心血管风险。本研究旨在探讨他汀类药物治疗对循环oxLDL的影响以及这种影响对颈动脉粥样硬化所致狭窄的可能作用。
共纳入100例颈动脉粥样硬化患者(男性76例,中位年龄68岁)。狭窄>70%的患者(n=50)先行颈动脉血管成形术预处理,而狭窄<70%的患者则接受保守治疗。两组均给予低剂量阿托伐他汀,并调整剂量以使低密度脂蛋白胆固醇维持在<100mg/dL。在1、3、6和12个月时测量人体测量学指标、完整血脂谱及oxLDL。在基线和12个月时通过超声评估狭窄情况。
12个月时血脂谱显著改善,oxLDL从基线时的62.26±22.03mg/dL降至12个月时的44.49±21.75mg/dL(P<0.001)。在侵袭性预处理组未观察到再狭窄;在保守治疗组,狭窄程度显著降低(47.6±13.2%对37.7±15.7%,P<0.001)。oxLDL的降低与狭窄程度的减轻相关(r=0.17,P=0.018)。多因素分析显示,oxLDL是再狭窄的独立危险因素(风险比=4.319,P<0.001)。
低剂量阿托伐他汀治疗的颈动脉粥样硬化患者oxLDL显著降低。此外,oxLDL可作为此类患者狭窄程度的一个指标。